


Synergie Gene/Cell Therapy Risk Protection

GENE THERAPY STOP LOSS FOR LARGE GROUP EMPLOYERS

Gene therapy is a technique that uses a gene or genes to treat, prevent, or cure disease or medical disorders. Gene therapy offers the promise of potential cures but it comes with unprecedented costs (\$2M to \$4M per treatment). Recent clinical trials show exceptional results and the pipeline is seeing rapid growth. Large groups that don't buy traditional stop-loss coverage are exposed to frequent and expensive claims. With Synergie Gene/Cell Therapy Risk Protection, large group employers avoid major rate increases and potential lasers at renewal due to a gene therapy hitting their stop-loss coverage.

Currently available therapies and costs

Nearly 15 new therapies are expected in 2024 with costs ranging from \$800K to \$4M per treatment.



Life-changing medicine

The U.S. Food and Drug Administration (FDA) approved gene therapies to treat members who have been diagnosed with one of the following:

- Inherited retinal disease
- Spinal muscular atrophy
- Cooley's anemia
- Cerebral adrenoleukodystrophy (CALD)
- Hemophilia A
- Hemophilia B
- Duchenne muscular dystrophy

A solution that offers peace of mind

By combining a risk pool mechanism with a protection program that covers the cost of the gene therapy ingredient, employer groups can offer the best possible care without feeling the impact of the extremely high cost.

What is stop-loss coverage?

Stop loss is coverage acquired by self-funded employers to provide a cap in high-cost claims. With the growth of gene therapy, many large group employers, regardless of funding type, are seeking a low-cost solution to mitigate these high-dollar claims.

How does Synergie Gene/Cell Therapy Risk Protection differ from traditional stop loss?

The key difference is that this risk protection is embedded with your LWAC stop-loss coverage. Synergie Gene/Cell Therapy Risk Protection only provides coverage for the gene therapy ingredient, making it a great fit for an employer that's covering gene therapy, or for an employer that wants to cover gene therapy without the risk of exorbitant costs.

What is the minimum group size for the Synergie Gene/Cell Therapy Risk Protection?

Synergie Gene/Cell Therapy Risk Protection is included for any group that buys LWAC stop loss and matches the group's individual stop-loss level regardless of size.

What gene therapies are included under this coverage?

As of September 1, 2023, seven of the FDA approved gene therapies are included in Synergie Gene/Cell Therapy Risk Protection:

- Luxturna
- Zolgensma
- Zynteglo
- Skysona
- Hemgenix
- Roctavian
- Elevidys

Why does Synergie Gene/Cell Therapy Risk Protection only cover ingredient cost?

The ingredient cost is the largest cost driver and is based on a wholesale acquisition cost. This expense can range from \$2M to \$4M. While a patient could have other expenses, such as the use of other specialty drugs or hospitalizations, this product is only intended to cover the gene therapy ingredient cost.

What about new gene therapies that come to market during the year?

LifeWise Assurance Company will continue to work with our partners to bring the most comprehensive and affordable risk management programs to the market. Our options to cover more therapies will be evaluated routinely as they become approved by the FDA.

Need more information? Contact your LifeWise Assurance Company representative today.